{"title": "A Method to Model Outbreaks of New Infectious Diseases with Pandemic Potential such as COVID-19", "doi": "10.1101/2020.03.11.20034512", "citation_id": "2020.03.11.20034512v1", "date": "2020-03-16", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.03.11.20034512", "abstract": "<p>The emergence of the novel coronavirus (a.k.a. COVID-19, SARS-CoV-2) out of Wuhan, Hubei Province, China caught the world by surprise. As the outbreak began to spread outside of China, too little was known about the virus to model its transmission with any acceptable accuracy. World governments responded to rampant minformation about the virus leading to collatoral disasters, such as plunging financial markets, that could have been avoided if better models of the outbreak had been available.\n\nThis is an engineering approach to model the spread of a new infectious disease from sparse data when little is known about the infectious agent itself. The most sought after estimate is the projected number of people who may be contagious, but still be within the incubation period thus remaining asymptomatic and undetected. This parameter is useful for estimating the extent of outbreak among a population over time and what to expect. It is thus important for common sense decision making by governments, organizations, and even individuals to contain, prepare, prevent, react, and safeguard. A Monte Carlo approach is implemented by using incubation period and a variable, called testing efficiency as variables.\n\nThe Coronavirus outbreak in USA will be used to illustrate the implementation of this modeling approach. Among others it is demonstrated that imposing early travel restrictions from infected countries slowed down the outbreak in the USA  by about 26 days.</p>", "twitter_description": "The emergence of the novel coronavirus (a.k.a. COVID-19, SARS-CoV-2) out of Wuhan, Hubei Province, China caught the world by surprise. As the outbreak began to spread outside of China, too little was known about the virus to model its transmission with any acceptable accuracy. World governments responded to rampant minformation about the virus leading to collatoral disasters, such as plunging financial markets, that could have been avoided if better models of the outbreak had been available. This is an engineering approach to model the spread of a new infectious disease from sparse data when little is known about the infectious agent itself. The most sought after estimate is the projected number of people who may be contagious, but still be within the incubation period thus remaining asymptomatic and undetected. This parameter is useful for estimating the extent of outbreak among a population over time and what to expect. It is thus important for common sense decision making by governments, organizations, and even individuals to contain, prepare, prevent, react, and safeguard. A Monte Carlo approach is implemented by using incubation period and a variable, called testing efficiency as variables. The Coronavirus outbreak in USA will be used to illustrate the implementation of this modeling approach. Among others it is demonstrated that imposing early travel restrictions from infected countries slowed down the outbreak in the USA by about 26 days.\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Funding Statement\n\nThis work was unfunded.\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nAll data is publicly available.\n\n<https://coronavirus.gov>", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.11.20034512v1.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.03.11.20034512v1", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.11.20034512v1.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/03/16/2020.03.11.20034512.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.03.11.20034512v1", "access_rights": "restricted", "authors": ["Willem G Odendaal"]}